The White House released a new national science strategy on July 24 titled “Science: A New Golden Age,” and the research community response has been anything but unified. The document, produced by the Office of Science and Technology Policy under director Michael Kratsios, outlines a vision for American science that shifts emphasis dramatically from biomedical and life sciences toward artificial intelligence, physical sciences, and engineering.
The report calls for reallocating federal research funding away from universities and toward private-sector technology companies, a structural change that would alter how basic science is conducted in the United States. It also proposes consolidating parts of the federal research apparatus, streamlining grant processes, and reducing regulatory barriers to commercial technology development.
The priorities shift
The blueprint’s core thesis is that American scientific leadership depends on dominating AI, quantum computing, advanced manufacturing, and energy technology. These areas receive sustained attention and proposed funding increases throughout the document. The life sciences, by contrast, are mentioned primarily in the context of how AI can accelerate biomedical discovery, rather than as a standalone priority.
This represents a departure from the science policy of recent decades. Since the doubling of the NIH budget in the late 1990s and early 2000s, biomedical research has been the dominant recipient of federal science spending. The new report does not explicitly propose cutting NIH or NSF budgets, but its emphasis signals a shift in where the administration believes marginal research dollars would deliver the greatest return.
The report also proposes expanding the role of the private sector in setting national research priorities. Industry-led consortia would have greater influence over what research gets funded. University researchers, who have traditionally driven basic science through investigator-initiated grants, would see their relative share of influence shrink under the proposed model.
Mixed reactions from the research community
The biomedical research community voiced immediate concern. The Association of American Medical Colleges issued a statement noting that the blueprint’s relative silence on life sciences funding comes at a time when the NIH budget has already been flat for several years, adjusted for inflation. The Federation of American Societies for Experimental Biology pointed out that the COVID-19 pandemic, mRNA vaccine development, and the rapid sequencing of new viral variants all depended on decades of sustained federal investment in basic biomedical research.
Supporters of the plan argue that the United States risks falling behind China and other competitors in AI and advanced manufacturing, areas where federal investment has been comparatively modest. They point to the CHIPS and Science Act of 2022 as a model: targeted government investment in semiconductor manufacturing catalyzed billions in private-sector construction. The new blueprint extends that logic to AI infrastructure, quantum computing, and energy technology.
The reaction from the physical sciences community was more measured but not uniformly enthusiastic. Some researchers noted that previous efforts to steer federal research toward specific priority areas, such as the National Nanotechnology Initiative and the Materials Genome Initiative, produced mixed results. Basic research, they argue, is difficult to direct from Washington. The most transformative discoveries often come from investigator-driven projects whose applications were not foreseeable at the outset.
Universities vs. industry
Perhaps the most consequential proposal in the document concerns who performs the research. The report suggests that federal research dollars should flow more heavily to technology companies and less to universities. It argues that industry can bring products to market faster and that the traditional academic model, with its peer-reviewed grant cycles and publication incentives, is too slow for the AI era.
Critics counter that industry research is inherently focused on applied problems with near-term commercial potential, while universities are where the fundamental science that enables those applications is conducted. The transistor, the laser, the algorithm behind Google’s search engine, and the mRNA platform used in COVID-19 vaccines all originated in academic laboratories, not corporate R&D centers.
The report also proposes reducing indirect cost payments to universities (the overhead that institutions charge on federal grants to cover facilities, administration, and compliance). University administrators warn that cutting indirect cost recovery would force them to reduce graduate student enrollments, defer laboratory maintenance, and scale back research infrastructure at a time when they are already competing with industry for talent.
What happens next
The “Science: A New Golden Age” report is a blueprint, not a budget. Translating its recommendations into federal policy would require legislation from Congress and appropriations decisions that are likely to be contentious. The NIH has strong bipartisan support on Capitol Hill, rooted in the popularity of biomedical research with constituents. Any attempt to shift resources away from health research would face significant opposition.
OSTP is expected to follow the blueprint with more detailed implementation plans in the coming months, including proposed legislative language and executive actions that the White House can take without Congress. The research community is watching closely. For university scientists, the stakes are existential: a sustained shift in funding from investigator-driven basic science to industry-led applied research would reshape the American research enterprise for a generation.